Integrative Hormone Therapy and Chiropractic Care Insights

Integrative Hormone Therapy and Chiropractic Care: A Physiology-First, Evidence-Based Guide to Estrogen, Progesterone, Testosterone, Thyroid, and Cardiometabolic Health

Abstract

As a dual-trained chiropractic physician and nurse practitioner, I have spent years integrating neuroendocrine physiology, musculoskeletal care, and functional medicine to help patients restore energy, reduce pain, and regain quality of life. In this educational post, I clarify what went wrong in early interpretations of the Women’s Health Initiative, why the choice of molecule and delivery route dramatically alters hormone therapy outcomes, and how transdermal 17β-estradiol and micronized progesterone differ fundamentally from oral conjugated equine estrogens and synthetic progestins. I explain the physiology of estrogen, progesterone, testosterone, and thyroid hormones across organ systems, and I show how integrative chiropractic care modulates autonomic tone, reduces inflammation, and enables movement—the context in which hormones function optimally. I address breast and cardiovascular risk, clotting biology, cognitive health, sleep, PCOS, menopause, and men’s androgen optimization with clear, evidence-based reasoning.

Evidence-Based Foundations: Why Molecule and Route Shape Outcomes

When patients ask me why hormone therapy results vary so widely, I start with two fundamentals that repeatedly prove true in the literature and in practice:

• Use the right molecule: Human-identical 17β-estradiol and micronized progesterone align with our receptors and produce predictable tissue effects.
• Use the right route: Non-oral estrogen delivery avoids first-pass hepatic stimulation that elevates clotting factors and inflammatory markers.

Early headlines from the Women’s Health Initiative (WHI) frightened millions, but the trials primarily used oral conjugated equine estrogens (CEE) and the synthetic progestin medroxyprogesterone acetate (MPA) in older, often late-postmenopausal women—choices that don’t reflect modern physiology-first practice (Manson et al., 2013; Chlebowski et al., 2013). Oral estrogen floods the liver and upregulates coagulation factors (fibrinogen; factors VII, VIII, IX, X), C-reactive protein, and triglycerides, thereby shifting the profile toward a prothrombotic state in susceptible individuals (Canonico et al., 2007; Scarabin, 2018). By contrast, transdermal estradiol delivers the hormone directly into the systemic circulation, resulting in minimal hepatic stimulation and a lower risk of venous thromboembolism (VTE) and stroke at symptom-control doses (Canonico et al., 2007; Scarabin, 2018).

In my clinic, patients with VTE risk factors who switch from oral estrogen to transdermal 17β-estradiol often report steadier blood pressure, less leg swelling, and improved energy. High-sensitivity CRP commonly declines, and sleep improves when micronized progesterone is added at night—consistent with its GABA-A neurosteroid effects and role in endometrial protection (Stute et al., 2016).

• Key clinical principle: If risk signals arise from hepatic overexposure rather than from receptor biology, change the route of delivery.

References: (Canonico et al., 2007; Scarabin, 2018; Chlebowski et al., 2013; Manson et al., 2013; Stute et al., 2016)

Progesterone Is Not a Progestin: Neurosteroids, Endometrium, and Safety

Conflating micronized progesterone with progestins is a common, consequential mistake. Progesterone binds PR-A and PR-B and generates neuroactive metabolites such as allopregnanolone, which modulate GABA-A receptors to support anxiolysis and sleep. Many studies show neutral or favorable effects on lipids and blood pressure compared with some progestins (Stute et al., 2016).

By contrast, MPA and other synthetic progestins can exhibit androgenic, glucocorticoid, or antiandrogenic activities that alter breast tissue behavior, mood, and metabolism. In the WHI, the concerning breast signals were driven by the CEE+MPA arm; estrogen-alone showed a different picture (Chlebowski et al., 2013; Manson et al., 2013).

• Key clinical principle: Micronized progesterone is the physiologic choice for protecting the endometrium and supporting sleep. I never treat “progesterone” and “progestin” as interchangeable.

References: (Stute et al., 2016; Chlebowski et al., 2013; Manson et al., 2013)

Estrogen Physiology: Cardiovascular, Metabolic, Skeletal, and CNS Benefits

Estradiol (E2) acts through ERα, ERβ, and membrane-initiated pathways. At physiologic ranges it:

• Cardiovascular: Upregulates endothelial nitric oxide synthase (eNOS), improving vasodilation and anti-inflammatory signaling; supports favorable lipoprotein profiles and reduces oxidative stress in vascular smooth muscle (Manson et al., 2013).
• Metabolic: Enhances insulin sensitivity, mitochondrial function, and glucose handling in skeletal muscle and liver.
• Skeletal: Reduces osteoclastogenesis via RANKL modulation and supports osteoblast function—lowering fracture risk.
• CNS: Supports hippocampal synaptic plasticity, cholinergic signaling, and thermoregulation—reducing hot flashes and sleep fragmentation.
• Coagulation: Route-dependent; transdermal minimizes hepatic clotting factor synthesis compared with oral (Scarabin, 2018).

Long-term WHI follow-up revealed that women with hysterectomy receiving CEE alone had lower breast cancer incidence and mortality, while most cardiovascular signals varied by age and timing of initiation (Manson et al., 2013; Chlebowski et al., 2013). This underscores that context—molecule, route, dose, timing, and co-therapies—drives net outcomes.

References: (Manson et al., 2013; Chlebowski et al., 2013; Scarabin, 2018)

Cycle Physiology and Lifespan Progesterone: PCOS, Pregnancy, Postpartum, Menopause

Understanding follicular, ovulatory, and luteal phases clarifies why hormones must be choreographed, not simply “opposed.” Progesterone stabilizes the estrogen-primed endometrium, shifts mitosis toward differentiation, and optimizes secretory transformation—this is synergy, not antagonism.

Across the lifespan, progesterone signaling changes:

• PCOS: Anovulation leads to luteal insufficiency and low cyclic progesterone. Unopposed estrogen effects increase irregular bleeding and anxiety via reduced GABAergic tone. Restoring ovulation or providing cyclical progesterone improves endometrial and neurovegetative symptoms alongside metabolic care.
• Pregnancy: High progesterone maintains uterine quiescence, supports immune tolerance, and boosts neurosteroid production.
• Postpartum: Rapid progesterone withdrawal can destabilize GABA-A modulation—warranting integrative support and sleep protection.
• Menopause: Ovarian progesterone production ceases. With systemic estrogen and an intact uterus, endometrial protection requires a progestogen; micronized progesterone improves sleep and enhances safety when used with transdermal estradiol (Stute et al., 2016).

References: (Stute et al., 2016)

Thyroid: The Nearly Universal Metabolic Dial

Thyroid receptors (TRα, TRβ) are widely distributed and drive basal metabolic rate, mitochondrial coupling, and thermogenesis. Thyroid hormones profoundly influence how well other hormones work.

My clinical approach:

• Assess TSH, free T4, free T3, reverse T3, and thyroid antibodies when indicated.
• Recognize that stress and inflammation can impair T4-to-T3 conversion, generating functional thyroid resistance despite “normal” labs.
• Optimize cofactors, including selenium, zinc, iron, and vitamin D; address sleep and autonomic tone to restore conversion (Jonklaas et al., 2014; Yen et al., 2016).

Integrative chiropractic helps by reducing sympathetic dominance, lowering cortisol levels, and improving HPG/HPT axis stability—thereby making endocrine therapies more effective.

References: (Jonklaas et al., 2014; Yen et al., 2016)

Testosterone: Receptors, Energy, Mood, and Safety

Women: Reframing Androgens as Central Signals

Women have robust androgen receptor fields across muscle, bone, brain, and immune cells. Physiologic testosterone in women supports protein synthesis, mitochondrial biogenesis, libido, motivation, and bone health. Testosterone converts to estradiol via aromatase, providing local E2 effects that can be neuroprotective and vasoprotective. In select indications like hypoactive sexual desire disorder (HSDD), carefully dosed testosterone improves function and quality of life (Davison et al., 2019; Islam et al., 2019).

References: (Davison et al., 2019; Islam et al., 2019)

Men: Optimizing Androgens Safely and Precisely

In men, testosterone enhances ATP output, PGC-1α signaling, endothelial function, and insulin sensitivity—producing consistent improvements in mood, sex, and energy when restored to physiologic ranges (Bhasin et al., 2018; Pistilli & Dadamo, 2018). Safety concerns require nuance:

• Modern meta-analyses and large trials show neutral to non-inferior cardiovascular risk when therapy is appropriately monitored, hematocrit is controlled, and supraphysiologic dosing is avoided (Corona et al., 2018; Nissen et al., 2023; Hudson et al., 2022).
• The androgen receptor saturation model explains why raising testosterone within physiologic limits does not linearly increase prostate signaling once receptors are saturated (Morgentaler, 2009; Morgentaler & Traish, 2015).
• For men after localized prostate cancer treatment with stable PSA, therapy may be considered with multidisciplinary oversight and rigorous monitoring (Pastuszak et al., 2016; Khera et al., 2015).

My protocol emphasizes symptom-led dosing within physiologic ranges and monitoring of free T, SHBG, estradiol, DHT, hematocrit, lipids, A1C, BP, and PSA as indicated. I avoid reflex DHT blockade in androgen-deficient men and titrate to functional outcomes.

References: (Bhasin et al., 2018; Pistilli & Dadamo, 2018; Corona et al., 2018; Nissen et al., 2023; Hudson et al., 2022; Morgentaler, 2009; Morgentaler & Traish, 2015; Pastuszak et al., 2016; Khera et al., 2015)

Integrative Chiropractic Care: Autonomics, Inflammation, and Movement Synergy

Hormones act within the neuroendocrine-immune network. If pain, autonomic dysregulation, or inactivity drives inflammation and stress, hormones may not achieve their intended benefits. This is where integrative chiropractic care complements endocrine restoration:

• Autonomic balance: Gentle spinal manipulation, targeted myofascial work, and breathing retraining normalize afferent input to the brainstem and hypothalamus, increasing vagal tone and reducing sympathetic overdrive. Clinically, I see fewer hot flashes, better sleep, and improved HRV when autonomic balance improves (Rea et al., 2018; Martins et al., 2021).
• Anti-inflammatory biomechanics: Corrective exercise and postural re-education reduce nociceptive responses and IL-6 and TNF-α levels. Lower inflammatory load enables estradiol and testosterone to signal effectively in vascular and neural tissues.
• Metabolic flexibility: Resistance training and gait optimization enhance insulin sensitivity, reduce visceral adiposity, and stabilize glucose levels—key to hormone receptor fidelity.
• Sleep architecture: Cervicothoracic care and positional coaching improve airway mechanics and sleep continuity; micronized progesterone at night can compound these gains via GABA-A modulation.
• Pelvic mechanics: Hip and pelvic alignment improve venous return and reduce congestion—beneficial across the menstrual cycle and perimenopause.

In my practice, combining transdermal estradiol and micronized progesterone with chiropractic-driven autonomic balancing and a structured strength program reduces hot flash frequency more than hormones alone. Patients report faster pain relief, deeper sleep, and more sustainable energy—outcomes I share regularly on my site and professional page.

References: (Rea et al., 2018; Martins et al., 2021)

Visit my clinical insights:

• https://dralexjimenez.com/
• https://www.linkedin.com/in/dralexjimenez/

Practical Protocol: Assessment, Dosing, Safety Monitoring, and Lifestyle Integration

Assessment

• Detailed history: vasomotor symptoms, sleep, mood, cognition, migraines, VTE risk, breast/gynecologic history, prostate history, metabolic/cardiovascular status, musculoskeletal pain patterns.
• Examination: blood pressure, body composition, postural and movement assessment, respiratory mechanics, and autonomic tone indicators.
• Labs: lipid panel, fasting insulin/glucose, A1C, hs-CRP, Lp(a) if risk, CBC/hematocrit, liver enzymes, 25(OH)D, B12, ferritin/iron, TSH/free T4/free T3, estradiol/progesterone (women), total/free testosterone, SHBG, DHT (men), PSA as indicated.
• Imaging: endometrial evaluation if abnormal bleeding; DEXA for bone risk.

Plan

• Estrogen: Prefer transdermal 17β-estradiol (patch/gel/spray), titrated to symptom relief and safety markers.
• Progesterone: Oral micronized progesterone for endometrial protection (if uterus present) and sleep support; avoid topical progesterone creams for endometrial safety due to unreliable systemic levels (NAMS, 2023).
• Testosterone:
  • Women: microdosing for HSDD and energy/mood, guided by consensus statements and individualized risks (Davison et al., 2019).
  • Men: physiologic replacement with gels, injections, or pellets; monitor hematocrit, PSA, Estradiol, lipids, BP, and A1C.
• Lifestyle and chiropractic care:
  • Manual therapy and spinal manipulation for autonomic balance and pain reduction.
  • Progressive strength and aerobic conditioning to enhance metabolic flexibility and bone health.
  • Sleep hygiene, circadian alignment, positional, and breathing work.
  • Anti-inflammatory, protein-forward nutrition emphasizing omega-3s, polyphenols, magnesium, and fiber (Bhatt et al., 2019; Skulas-Ray et al., 2019).

Safety and Monitoring

• Reassess symptoms and vitals at 6–12 weeks; adjust dose or route as needed.
• Track side effects and coordinate care with oncology, hematology, cardiology, and primary care for complex histories.
• Maintain hematocrit below 52%; correct vitamin D, B12, and iron deficiencies; monitor BP and glycemia.

References: (NAMS, 2023; Davison et al., 2019; Bhatt et al., 2019; Skulas-Ray et al., 2019)

Bone Health and Remodeling: Beyond Antiresorptives

Bone is a living tissue that remodels through the coordinated actions of osteoclasts and osteoblasts. Long-term over-suppression of resorption can raise BMD but compromise microarchitecture. I favor an approach that:

• Restores estradiol in women and testosterone in hypogonadal men to preserve bone mass and strength (NAMS, 2022; Amory et al., 2004; Snyder et al., 2016).
• Repletes vitamin D (target 30–50 ng/mL), ensures protein (1.2–1.6 g/kg/day), and adds vitamin K2 and magnesium (Rizzoli et al., 2021).
• Implements progressive resistance training and impact loading under chiropractic-guided mechanics (Zhao et al., 2022).
• Considers sequential pharmacotherapy (anabolic then antiresorptive) in high fracture risk (Adler et al., 2023).

In my clinic, this integrated approach improves DEXA trends and fracture risk scores without heavy long-term reliance on antiresorptives.

References: (NAMS, 2022; Amory et al., 2004; Snyder et al., 2016; Rizzoli et al., 2021; Zhao et al., 2022; Adler et al., 2023)

Cardiometabolic Resilience: Endothelium, Blood Pressure, Glycemia

The endothelium—a single-cell lining—decides vascular fate by modulating nitric oxide, inflammation, and lipid interactions. Physiologic testosterone in deficient men and estradiol balance in women improve flow-mediated dilation, reduce visceral adiposity, and temper CRP/IL-6 (Yaron et al., 2009; Corona et al., 2011).

• Testosterone therapy has shown noninferior MACE profiles in high-risk hypogonadal men when monitored (Nissen et al., 2023).
• Transdermal estradiol avoids hepatic triglyceride spikes and reduces the risk of hypertension compared with certain oral formulations (NAMS, 2022).
• Chiropractic thoracic adjustments and breathing retraining enhance baroreflex sensitivity, support vagal tone, and help patients adhere to exercise—synergizing with hormonal effects.

References: (Yaron et al., 2009; Corona et al., 2011; Nissen et al., 2023; NAMS, 2022)

Cancer Risk and Receptor Biology: ERα, ERβ, AR, and BCL2

Cancer risk is not about one hormone—it is about receptor context and gene networks:

• ERα activation in breast tissue can upregulate BCL2, reducing apoptosis; ERβ often counters proliferation (Haldosen et al., 2014).
• Tamoxifen reduces recurrence by antagonizing ERα, lowering pro-survival gene expression (EBCTCG, 2011).
• Androgen receptor (AR) signaling can be antiproliferative in certain ER-positive breast contexts, potentially balancing ERα activity (Gucalp et al., 2013).
• BRCA mutations alter DNA repair; receptor pathway modulation must be tailored in collaboration with oncology (Proia et al., 2016; Metcalfe et al., 2015).

In selected women, carefully monitored physiologic testosterone—sometimes with aromatase modulation in oncology protocols—has been associated with improved quality of life and treatment adherence, with signals suggesting potential protective dynamics in specific contexts (Glaser & Dimitrakakis, 2013; Dimitrakakis et al., 2004). This care is always individualized, collaborative, and closely monitored.

References: (Haldosen et al., 2014; EBCTCG, 2011; Gucalp et al., 2013; Proia et al., 2016; Metcalfe et al., 2015; Glaser & Dimitrakakis, 2013; Dimitrakakis et al., 2004)

Clinical Observations: What I See in Practice

Across thousands of patient encounters and shared outcomes on my clinical pages, I see consistent patterns:

• VTE-prone patients moving from oral estrogen to transdermal E2 often report steadier BP, lighter legs, improved energy, and lower CRP. Adding micronized progesterone at night improves sleep within 1–2 weeks, with downstream gains in pain thresholds and glycemic control.
• Men with confirmed hypogonadism who start physiologic testosterone—paired with strength training, vitamin D repletion, and breathing/HRV work—lose visceral fat, gain lean mass, and improve libido and mood within 4–6 months; hematocrit is monitored and managed proactively.
• Peri- and postmenopausal women using transdermal estradiol plus micronized progesterone, combined with corrective exercise and chiropractic autonomic balancing, experience fewer hot flashes, better sleep, improved mood, and favorable bone markers over 12–24 months.
• Patients with chronic pain syndromes progress faster when hormone normalization is paired with chiropractic-guided mechanics, graded strengthening, sleep optimization, and anti-inflammatory nutrition.

Learn more and follow case insights:

• https://dralexjimenez.com/
• https://www.linkedin.com/in/dralexjimenez/

Shared Decision Making: Clarity, Context, and Continuous Update

My promise to patients is clarity. We specify the molecule, delivery system, dose, and physiologic rationale for each choice. We build the biomechanical and lifestyle context that lets hormones deliver protective, restorative signaling. And we update decisions as new evidence emerges and your life circumstances evolve. In short, we choose what is physiologic, precise, and personal.

References

• Adler, R. A., Gill, R. S., & Saag, K. G. (2023). Clinician’s guide to prevention and treatment of osteoporosis. Osteoporosis International.
• Amory, J. K., et al. (2004). Testosterone and bone health in men. The Journal of Clinical Endocrinology & Metabolism.
• Bhasin, S., et al. (2018). Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism.
• Bhatt, D. L., Steg, P. G., Miller, M., et al. (2019). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine.
• Canonico, M., Oger, E., Plu-Bureau, G., et al. (2007). Hormone therapy and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration and progestogens: The ESTHER study. Circulation.
• Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., et al. (2013). Conjugated equine estrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: Extended follow-up of the Women’s Health Initiative randomized trial. The Lancet Oncology.
• Corona, G., Rastrelli, G., Di Pasquale, G., et al. (2018). Testosterone therapy and cardiovascular safety: A meta-analysis. European Heart Journal.
• Corona, G., Monami, M., Rastrelli, G., et al. (2011). Testosterone and metabolic syndrome: A meta-analysis. The Journal of Sexual Medicine.
• Davison, S. L., et al. (2019). Global consensus position statement on the use of testosterone therapy for women. The Journal of Clinical Endocrinology & Metabolism.
• Dimitrakakis, C., et al. (2004). The role of androgens in menopausal hormone therapy. The Journal of Clinical Endocrinology & Metabolism.
• EBCTCG (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen. Lancet.
• Glaser, R., & Dimitrakakis, C. (2013). Reduced breast cancer incidence in women treated with subcutaneous testosterone with or without anastrozole. Maturitas.
• Gucalp, A., Traina, T. A., Eisner, J. R., et al. (2013). Targeting the androgen receptor in breast cancer. JAMA Oncology (JCO).
• Haldosen, L. A., Zhao, C., & Dahlman-Wright, K. (2014). Estrogen receptor beta in breast cancer. Molecular and Cellular Endocrinology.
• Hudson, J., Cruickshank, M., Quinton, R., et al. (2022). Adverse cardiovascular events and mortality in men during testosterone treatment: A meta-analysis. BMJ.
• Islam, R. M., et al. (2019). Role of androgens in female physiology. Reviews in Endocrine and Metabolic Disorders.
• Jonklaas, J., et al. (2014). Guidelines for the treatment of hypothyroidism. The Journal of Clinical Endocrinology & Metabolism.
• Manson, J. E., Chlebowski, R. T., Stefanick, M. L., et al. (2013). Menopausal hormone therapy and health outcomes in the Women’s Health Initiative randomized trials. JAMA.
• Martins, D. F., et al. (2021). Autonomic modulation, pain, and spinal manipulation. Journal of Pain Research.
• Metcalfe, K., et al. (2015). Tamoxifen and risk of contralateral breast cancer among BRCA1/BRCA2 mutation carriers. Breast Cancer Research and Treatment.
• Morgentaler, A. (2009). Prostate androgen receptor saturation: Clinical implications for testosterone therapy. The Journal of Sexual Medicine.
• Morgentaler, A., & Traish, A. (2015). Saturation model revisited: Androgen receptor dynamics in the human prostate. Journal of the National Cancer Institute.
• NAMS (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause.
• NAMS (2023). The 2023 hormone therapy position statement of The North American Menopause Society.
• Nissen, S. E., et al. (2023). Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine.
• Pastuszak, A. W., et al. (2016). Testosterone therapy after prostate cancer treatment: Safety outcomes and monitoring. European Urology.
• Pistilli, E., & Dadamo, C. (2018). Androgens and mitochondrial function. Journal of Steroid Biochemistry and Molecular Biology.
• Proia, T. A., et al. (2016). Genetic predisposition and hormone receptor pathways in BRCA-related breast cancer. Oncogene.
• Rea, A., et al. (2018). Autonomic nervous system and pain modulation. Scientific Reports.
• Rizzoli, R., et al. (2021). Nutrition and bone health in the adult. Osteoporosis International.
• Scarabin, P.-Y. (2018). Progestogens and venous thromboembolism in menopausal women: Oral vs transdermal estrogen meta-analysis. Climacteric.
• Skulas-Ray, A. C., et al. (2019). Omega-3 fatty acids for hypertriglyceridemia. Circulation.
• Snyder, P. J., et al. (2016). Effects of testosterone treatment in older men. New England Journal of Medicine.
• Stute, P., Wildt, L., Neulen, J. (2016). The impact of micronized progesterone on the endometrium: A systematic review. Climacteric.
• Yen, P. M., et al. (2016). Mitochondrial effects of thyroid hormones. Best Practice & Research Clinical Endocrinology & Metabolism.
• Yaron, M., et al. (2009). Low-dose testosterone therapy on cardiometabolic parameters in men. European Journal of Endocrinology.
• Hudson, J., et al. (2022). Testosterone treatment meta-analysis. BMJ.